BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22914968)

  • 1. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
    Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
    Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of
    Hasebe M; Yoshikawa K; Nishii R; Kawaguchi K; Kamada T; Hamada Y
    Int J Oral Maxillofac Surg; 2017 Oct; 46(10):1220-1228. PubMed ID: 28535963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
    Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers.
    Hoshikawa H; Yamamoto Y; Mori T; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Ann Nucl Med; 2014 Dec; 28(10):1020-6. PubMed ID: 25179522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/CT with 3'-deoxy-3'-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy.
    Saga T; Koizumi M; Inubushi M; Yoshikawa K; Tanimoto K; Fukumura T; Miyamoto T; Nakajima M; Yamamoto N; Baba M
    Nucl Med Commun; 2011 May; 32(5):348-55. PubMed ID: 21326122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
    Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
    Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ( 18 ) F-FLT PET and ( 18 ) F-FDG PET for detection of cervical lymph node metastases in head and neck cancers.
    Hoshikawa H; Kishino T; Mori T; Nishiyama Y; Yamamoto Y; Inamoto R; Akiyama K; Mori N
    Acta Otolaryngol; 2012 Dec; 132(12):1347-54. PubMed ID: 22992199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography as an effective diagnostic workup in cervical metastasis of carcinoma from an unknown primary tumor.
    Zhao K; Luo XM; Zhou SH; Liu JH; Yan SX; Lu ZJ; Yang SY; Lin LL; Dong MJ
    Cancer Biother Radiopharm; 2012 Dec; 27(10):685-93. PubMed ID: 22834634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.
    Huang WY; Kao CH; Huang WS; Chen CM; Chang LP; Lee MS; Chao HL; Chiu CH; Lo CH; Jen YM
    J Nucl Med; 2013 Oct; 54(10):1710-6. PubMed ID: 23970365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
    Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
    J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy.
    Romesser PB; Qureshi MM; Shah BA; Chatburn LT; Jalisi S; Devaiah AK; Subramaniam RM; Truong MT
    Ann Nucl Med; 2012 Aug; 26(7):527-34. PubMed ID: 22610386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.